Ultragenyx Pharmaceutical RARE Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

Ionis PharmaceuticalsIONS

——

ModernaMRNA

——

BridgeBio PharmaBBIO

——

ANI PharmaceuticalsANIP

——

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's payments to acquire intangible assets?: Ultragenyx Pharmaceutical (RARE) reported payments to acquire intangible assets of $5M in Q1 2026.
How has Ultragenyx Pharmaceutical's payments to acquire intangible assets changed year-over-year?: Ultragenyx Pharmaceutical's payments to acquire intangible assets decreased by 66.7% year-over-year, from $15M to $5M.